AlphaMaven AlphaMaven

CVC walks away from its €3B IRCA takeover after a forensic review, setting up a rare private equity clash with Advent

Reported by Dealroom
Nov 17, 2026· 2 min read
Save Post LinkedIn Email
Key Takeaways
  • • CVC Capital Partners said on 17 November 2026 that it will not complete its nearly €3 billion (about $3.3 billion) acquisition of Italian ingredients group IRCA from Advent International, calling the transaction "no longer viable" after forensic analysis of diligence information.
  • • Advent "strongly rejects" CVC's attempt to withdraw from a signed, binding agreement and says it will take all appropriate steps to protect its rights, with any unresolved dispute headed to arbitration.
  • • CVC agreed in June 2026 to buy IRCA through its Fund IX after an auction that drew several binding offers; closing had been expected in the fourth quarter.
  • • Buyout firms rarely walk away from signed takeovers, so the dispute between two of Europe's most active private equity firms could become one of the industry's largest legal fights.
Summary
CVC Capital Partners said on Tuesday, 17 November 2026, that it will not complete its nearly €3 billion (about $3.3 billion) acquisition of Italian ingredients group IRCA from Advent International. In a statement, CVC said "extensive forensic analysis of the information that was provided to us during due diligence revealed that the Transaction is no longer viable," adding that it was acting in the best interests of its investors. The Financial Times first reported the move on Monday evening, saying CVC had informed Advent several weeks earlier.

Advent responded that it "strongly rejects CVC's attempt to withdraw from a signed, binding agreement," saying the deal was agreed after extensive due diligence and that it stands behind the integrity of the sale process. According to the FT, Advent will take all appropriate steps to protect its rights, and an unresolved dispute would go to arbitration between the two firms. IRCA declined to comment.

CVC agreed in June 2026 to buy IRCA through its Fund IX, winning an auction that drew several binding offers. Advent acquired IRCA in 2022. IRCA makes ingredients and semi-finished products for pastry, bakery, chocolate and ice cream, employs more than 2,200 people and operates 19 plants in Europe, the US and Vietnam. The FT reports that CVC has also argued IRCA's performance deteriorated after signing, as cocoa and other commodity prices rose and demand softened.

The standoff is notable because buyout firms almost never walk away from signed takeovers; previous cases were usually tied to shocks such as the 2008 financial crisis or the Covid-19 pandemic. A dispute between two of Europe's most active private equity firms over a seller's numbers could become one of the industry's largest legal disputes.

Go deeper than the headline

Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.

Start your free 7-day trial

Sources

1 outlet

AlphaMaven summarised this story from the reporting below. Each link opens the original article.

Dealroom CVC walks away from its €3B IRCA takeover after a forensic review, setting up a rare private equity clash with Advent